Human Anatomy, Physiology, and Medicine. Anything human!
okay, so they do use Bt !
Read it here:
June 17, 2005
Insects develop resistance to engineered crops when single- and double-gene altered plants are in proximity Cornell researchers say
and look at these: Bt Broccoli. WTHell????
Great find ( your post on Horowitz). Horowitz is where I got the info
on the patent/key holder of the HIV virus is Dr. Venter.
Nixon warned them in 1972 saying something to the effect that they need
to control the population of Sub Sahara. Is this not saying they wanted to wipe-out the black man?
I also think why TAm is not saying one disease or another is because
there are so many involved.....One of us may have our " batch" touched with something that causes Malaria, some of might have the "batch' where the crazy scientist threw in Typhoid Fever, or Cholera, or Leprosy, etc., Hence multiple clones of multiple diseases.
I really think tamtam is trying to tell us it is simply Bt poisioning. I.E.,
(which is really the same as B. Anthracis- aka ANTHRAX!!!)
Some even consider this the same species as well.
What's your take on this?
Randy, Can you share the hyperlink to the article on previous page re:
Bt Bacillus Thuringenesis is round rod.
Ba Bacillus Anthracus is more oblong.
Shapes are different. But, I am wondering, I am finding black soot like stuff under calluses.
Sometimes rods are oblong or mishapen. I wonder if they mixed them both together.
and skytroll I have noticed the black looking pieces of skin ( in very little bitty areas around SOME of my infected areas. It looks like maybe a lblack mold some would say......but all this is is Coal!
This has got to be it. You know that i researched everything under the sun
as referring to the years TamTam said these events occurred.
Well here you go ( choices) Uranium, smallpox, cloning and anthrax,
I just feel it is anthrax. Take that mix it with all the pollution (both air and water and land) and all the crap elese.....cloning & chemtrails....
We are going to hell in a handbasket.
Please, go back and skim that first hyperlink from Cornell on Bt....
Well here's some BIG-TIME NEWS.........THIS IS JUST A SNIPPET OF THE WEALTH OF INFORMATION THIS CO. HAS....AND THEY ARE TEAMED UP W/ DUPONT , STARLINK and all the BiG Boys..even got some cash from our nice little Government ( I FOUND THIS site when I Was lookng on the
"Securities and Exchange Commision"
check this out:
Current Fields of Application
We are currently applying our technologies to high-value opportunities in the fields of human therapeutics (protein pharmaceuticals and preventative and therapeutic vaccines) and industrial applications (agriculture and chemicals). Human Therapeutics
Our human therapeutics business, consisting of protein pharmaceuticals and preventative and therapeutic vaccines, presents us with opportunities in a wide variety of disease indications for which there is a significant unmet medical need for safe and effective treatments. The markets for many of these disease indications are very large and are summarized in the table below.
Cancer $20 billion
Infectious disease $20 billion
Blood Disorders $9 billion
Arthritis $8 billion
Multiple sclerosis $1.8 billion
Source: *MedAdNews May 2001
We are dedicated to becoming one of the world’s leading providers of improved, proprietary, protein-based therapeutics.
Market Opportunity. In 2000, worldwide sales of therapeutic proteins made using recombinant DNA technology exceeded $20 billion. Protein pharmaceutical products, such as erythropoietin and granulocyte colony stimulating factor, represent some of the world’s highest revenue pharmaceutical products. The protein therapeutics sector is one of the fastest growing sectors of the pharmaceutical market, with an annual sales growth rate of 5 to 15%. However, many presently marketed protein pharmaceuticals have limitations and harmful side effects. Most protein pharmaceuticals have short half-lives, which may result in the need for frequent administration of expensive, painful injections or intravenous treatments. Proteins can also be immunogenic, potentially leading to adverse side effects or reduced therapeutic efficacy. Examples of therapeutic proteins made using recombinant DNA technology, their 2000 worldwide sales and potential improvements that could be made to proteins currently being marketed are listed below:
2000 Sales ($US)
Erythropoietin $ 5.3 billion Longer half life
Interferons $ 3.4 billion Fewer side effects, longer half life
Insulin $ 3.1 billion Lower manufacturing cost
Human growth hormone $ 1.5 billion Longer half life
Colony stimulating factors $ 1.6 billion Longer half life
Clotting Factors $ 1.2 billion Longer half life, reduced immunogenicity
Interleukins $ 160 million Fewer side effects
By applying our technologies we believe we will be able to develop potent and safe protein pharmaceuticals that help address the limitations of current protein pharmaceuticals. Our technology offers a means both to develop new therapeutics, with better commercial and therapeutic attributes than naturally occurring proteins, and to develop improved next-generation protein drugs.
Applying our technology to validated targets can potentially reduce product development risk as well as accelerate the discovery and early-development phases of a drug candidate. While protein pharmaceuticals made from naturally occurring proteins can address large markets, they are often not well suited for commercialization without modification. Our integrated platform of proprietary technologies, including our MolecularBreeding directed molecular evolution technologies and post-translational modification capabilities, can help transform proteins into more potent, efficient and safer pharmaceuticals with suitable duration of action.
Business Strategy. Our strategy for protein pharmaceuticals is to partner and independently develop new and improved therapeutic products. Biopharmaceuticals at all stages of development—research, clinical, marketed or failed—are potential targets for improvement. We are currently building internal pre-clinical and clinical capabilities to allow us to move multiple products through the approval processes in the United States, Europe, and other important markets. In parallel, we are working with pharmaceutical companies to develop, manufacture and commercialize biopharmaceutical candidates made using our technologies. By collaborating with leading pharmaceutical companies and creating better versions of proven protein therapeutics we can maximize our return and decrease our development risk. Additionally, the speed of our technologies allows multiple potential products to be pursued simultaneously, thus decreasing portfolio risk.
Our protein pharmaceuticals activities were expanded considerably in August 2000 by our acquisition of Maxygen ApS (then known as Profound Pharma A/S), a Danish company, which contributed protein modification technologies and capabilities, as well as strong additions to our management team with drug development expertise. With the acquisition of Maxygen ApS, our research-stage protein pharmaceutical product pipeline was doubled. We have also benefited by additional expertise related to all stages of protein
A second approach, directed [color=red]molecular evolution, seeks to improve genes for commercial purposes by mimicking the natural events of evolution. There are two general approaches to directed molecular evolution, those utilizing targeted mutagenesis and those utilizing recombination-based techniques. Targeted mutagenesis involves the mutation of genes at preselected sites, most of which are harmful to gene function. The mutated genes are then screened to determine which mutations have [/color]resulted in improved attributes. Since targeted mutation has a low probability of improving a gene or sequence of complex biological reactions, screening for positive changes is expensive and time consuming. The second approach to directed molecular evolution involves recombination-based techniques, which mimic naturally occurring sexual recombination, a process in which regions of DNA are exchanged between strands of DNA. As recombination-based techniques do not require an understanding of the underlying biological process, and do not generate as many harmful changes as random mutagenesis, use of this approach is generally less costly and less time intensive than genomics, rational design or targeted mutagenesis approaches.
THIS COMPANY'S NAME IS: MAXYGEN
HERE'S SHORTER VERSION ON DIFFERENT WEEBSITE: http://www.prnewswire.com/cgi-bin/stori ... 482&EDATE=
Great find London!!
This is something I've been struggling with for quite a while when trying to get other people to consider the ideas presented by C3.
Regarding work being done by Maxygen:
How funny life becomes. You were just a regular person. Now your free time consists only of trying to become a friggin scientist. Yea, and I said science, like I am actually gonna need to know all about that in 20 years.
Biomimetic Manufacturing of Fibers
Our goals for this project were to:
1) Identify the fundamental molecular biology required for the clonal production
fiber forming protein polymers through genetic expression in yeast and
2) Study arachnid biology for silk production and lay the foundation for
application of that biology to protein fiber wet spinning.
Here ya go:
TRANSGENIC FIBER PRODUCING PLANTS WITH INCREASED EXPRESSION OF SUCROSE PHOSPHATE SYNTHASE FIELD OF THE INVENTION The present invention relates to a method for increasing the yield or quality of product from a plant by altering the expression of sucrose phosphate synthase. In particular, the present invention provides a transgenic cotton plant that has an increased level of sucrose phosphate synthetase relative to a non-transgenic cotton plant. Methods are also provided for increasing the yield or the quality of cotton fiber and the yield of cotton seed produced from a cotton plant. General methods are provided for regulating the thickness of cell walls, for increasing the yield and quality of other plant fibers, for regulating the ratio of cellulose to other dry weight components of the plant, for increasing seed yield, and for increasing tolerance of photosynthetic efficiency to cool night temperatures.
BACKGROUND OF THE INVENTION The control of high-rate cellulose production and its regulation by temperature are critical to agriculture, since all plant growth (and hence the production of all food crops) depends on cellulose synthesis to build cell walls throughout the vegetative and reproductive parts of the plant. The cellulose within the primary walls of all cells of the plant body is also of direct industrial importance as a digestible part of animal forage and for manufacture of thickeners, ethanol, and other cellulose-based or cellulose-derived products. Furthermore, plant parts based on secondary cell walls with high cellulose content are contained in or compose economically important plant products, including cotton fibers, wood, and fibers in forage crops. The agronomic productivity and product quality of wood and cotton, as well as other fiber crops such as hemp and flax, are in large part determined by the biosynthesis of cellulose. Therefore, an understanding of the basic regulatory mechanisms of cellulose synthesis and how it responds to temperature stress allows for beneficial changes in crop plants (improved product yield and quality) through genetic engineering.
Since cotton fiber weight is more than 90% cellulose, cotton is one particular crop where enhancing the flow of carbon to cellulose production can increase yield and quality. This will be an especially beneficial outcome if it is achievable under diverse environmental conditions encountered in cotton production fields, including cool night temperatures that hinder cotton fiber development. For example, it is known that cool night temperatures hinder the seasonal yield and quality of cotton fiber (Gipson, "Temperature Effects on Growth, Development, and Fiber Properties,"in Mauney, eds., Cotton Physiology, The Cotton Foundation: Memphis, pp. 47-56) because they hinder the rate of cellulose synthesis (Roberts et al.,"Effects of Cycling Temperatures on Fiber Metabolism in Cultured Cotton Ovules,"Plant Phvsiol., 100: 979-986 (1992)). The ability to manipulate cotton yield and fiber quality parameters and sustain or improve them under diverse and/or stressful environmental conditions will allow for beneficial changes in crop plants (improved product quality) through genetic engineering.
http://www.wipo.int/cgi-pct/guest/getby ... T_SET=DECL
Controlling Organelle Positioning: A Novel Chloroplast Movement Protein
Regarding the fibers found in the lesions. I recall about 10 years
ago having a plantars wart on my foot. If anyone is familiar with
plantars warts, they grow inward with roots in the foot. They are
difficult to get rid of, but none the less I succeeded in ridding
myself of it.
But I also recall seeing black root like fibers within the wart as
I would dig it out daily and apply the killing poison liquid. I
had always thought what a nightmare it would be to have such
an inward growing wart on another part of my body. These
fiber / lesions you are describing remind me a great deal of
the plantars wart I had on my foot.
I wonder if they are related.
Who is online
Users browsing this forum: No registered users and 0 guests